Sun Pharmaceutical Industries Ltd's Q4FY25 Quarter Results
- 23 May 2025
Result Summary
- Sun Pharmaceutical Industries Ltd reported a 11.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 11.4%.
- Its expenses for the quarter were down by 6.5% QoQ and up 8.8% YoY.
- The net profit decreased 8.7% QoQ and increased 34.1% YoY.
- The earnings per share (EPS) of Sun Pharmaceutical Industries Ltd stood at 11.1 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 12588.84 | 14141.08 | 11303.95 | -11.0% | 11.4% |
Total Expenses | 9671.68 | 10348.51 | 8892.81 | -6.5% | 8.8% |
Profit Before Tax | 2815.52 | 3476.40 | 2239.69 | -19.0% | 25.7% |
Tax | 148.93 | 558.86 | 222.91 | -73.4% | -33.2% |
Profit After Tax | 2658.74 | 2912.98 | 1982.90 | -8.7% | 34.1% |
Earnings Per Share | 11.10 | 12.10 | 8.30 | -8.3% | 33.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Sun Pharmaceutical Industries Ltd is a leading pharmaceutical company, primarily engaged in the manufacturing and distribution of pharmaceutical formulations and active pharmaceutical ingredients. As a prominent player in the industry, the company offers a wide range of products across chronic and acute therapeutic segments. It operates globally, with a significant presence in markets including the United States, India, and other countries. Sun Pharma is known for its focus on innovation and has a robust pipeline of generic and specialty drugs. Recent developments include strategic acquisitions and partnerships to enhance its portfolio and expand its geographic reach. However, specific recent developments or changes in business strategy are not detailed in the provided data.
Revenue
In the fourth quarter of the fiscal year 2025 (Q4FY25), Sun Pharmaceutical Industries Ltd reported a total income of ₹12,588.84 crores. This figure represents an 11.4% increase compared to the same quarter in the previous year (Q4FY24), where total income was ₹11,303.95 crores. However, there was a decline of 11.0% in total income on a quarter-over-quarter basis when compared to the third quarter of the fiscal year 2025 (Q3FY25), which recorded a total income of ₹14,141.08 crores. These changes reflect the periodic fluctuations in revenue generation over the analyzed periods.
Profitability
Sun Pharmaceutical Industries Ltd's profitability metrics for Q4FY25 indicate a profit before tax of ₹2,815.52 crores, which is a 25.7% increase from the ₹2,239.69 crores reported in Q4FY24. However, this marks a 19.0% decrease from the previous quarter (Q3FY25) where the profit before tax was ₹3,476.40 crores. The company paid ₹148.93 crores in taxes in Q4FY25, significantly lower than the ₹558.86 crores in Q3FY25, marking a 73.4% decrease. Year-over-year, taxes decreased by 33.2% from ₹222.91 crores in Q4FY24. The profit after tax for Q4FY25 was ₹2,658.74 crores, which grew by 34.1% compared to Q4FY24, but fell by 8.7% from Q3FY25. The earnings per share in Q4FY25 was ₹11.10, reflecting a year-over-year increase of 33.7% from ₹8.30 in Q4FY24, although it decreased by 8.3% from ₹12.10 in Q3FY25.
Operating Metrics
The financial data for Sun Pharmaceutical Industries Ltd shows total expenses of ₹9,671.68 crores for Q4FY25, an increase of 8.8% from ₹8,892.81 crores in Q4FY24. The expenses decreased by 6.5% from ₹10,348.51 crores in Q3FY25. These figures indicate variations in the company's cost management and operational activities. The operating metrics reflect how adjustments in expenses have contributed to the changes in profit margins and overall financial performance. The data does not include specific operational metrics such as production volumes or market share, focusing instead on the financial outcomes of the company's operations.
